Literature DB >> 1955697

Pneumococcal pneumonia including diagnosis and therapy of infection caused by penicillin-resistant strains.

D M Musher1.   

Abstract

Attempts to rank causative agents of pneumonia in adults have placed Streptococcus pneumoniae at the top of the list. Until 10 years ago, virtually all pneumococci isolated in the United States were susceptible to less than or equal to 0.02 micrograms/mL penicillin; however, the incidence of disease caused by moderately penicillin-resistant strains has increased in the United States in the past decade. This article reviews the role of S. pneumoniae in causing pneumonia, the best methods to make the diagnosis, and the appropriate means of treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955697

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  4 in total

Review 1.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

2.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Greece.

Authors:  S Kanavaki; S Karabela; E Marinis; N J Legakis
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

4.  Serotype distribution and antibiotics susceptibility pattern of Streptococcus pneumonia in Iran.

Authors:  Samira Habibian; Ali Mehrabi-Tavana; Zyanab Ahmadi; Morteza Izadi; Nematolah Jonaidi; Jalalodin Darakhshanpoure; Mahmode Salesi; Seyed Mohsen Zahraei; Ramezan Ali Ataee
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.